Sjögren Syndrome
ICD-10 M35.0 · ICD-11 4A43.2

Sjögren Syndrome with Active Arthritis: Next-Line Protocol When Glucocorticoids Fail to Achieve ESSDAI Response

This protocol addresses Sjögren syndrome with objective arthritis — inflammation of one or more joints — and active systemic disease (clinESSDAI score ≥1). It is indicated when initial glucocorticoid therapy has not produced the required reduction in global disease activity.

Clinical Scenario

The patient has Sjögren syndrome with joint involvement confirmed by objective signs — heat, redness, or swelling in one or more joints on physical examination, with ultrasound support when findings are uncertain. Active systemic disease is present (clinESSDAI ≥1). ESSDAI severity of arthritis is stratified by the number of affected joints.

Previous Line — Goal Not Achieved

Initial systemic management used glucocorticoids. The required therapeutic target — a reduction of ≥3 points in the global ESSDAI score — was not reached, triggering escalation to this next-line protocol.

Next-Line Approach

After glucocorticoid failure, management transitions to glucocorticoid-sparing immunosuppressive therapy. Several agents within this class are applicable; the choice is guided by individual patient characteristics and comorbidity profile — the complete selection and sequencing are available in the full protocol.

Target: reduction of ≥3 points in the global ESSDAI score
Instant Access to Structured Evidence-Based Regimens
References
Arthritis is clinically diagnosed on the basis of objective inflammation of ≥1 joints (heat, redness and swelling in the physical examination of the affected joint) supported by ultrasound studies when in doubt, and the ESSDAI score classifies the severity of arthritis according to the number of joints involved (moderate <5 joints, high >5).
The lack of head-to-head studies comparing the efficacy and safety profile of immunosuppressive agents in primary SjS-2002 (leflunomide, methotrexate, azathioprine, mycophenolate, cyclophosphamide) does not permit a recommendation on the use of one agent over another, except when patient characteristics or comorbidities are considered with respect to the safety profile.
With respect to the definition of the therapeutic response in systemic SjS, the TF recommends using a reduction of ≥3 points in the global ESSDAI score.
DOI: 10.1136/annrheumdis-2019-216114
View source ↗